Open
Pediatric Ravulizumab Study
To test the effectiveness and safety of the drug ravulizumab in patients aged 6-18 years.
Age & Gender
- 6 years ~ 17 years
- Male, Female, Gender Inclusive
Visit Availability
- Standard business hours (M-F, 8-5)
Location
United States (Nationwide)
What will be asked of you
Participant will asked questions about their MG and how it affects activities of daily living; in addition Parents/legal guardians will be asked about changes in medications. Blood will be drawn at every visit and study drug will be administered via IV line
Incentives
Gas mileage , hotel stay for out of town patients and meals
In-person visits:
30
30
Phone or online visits:
3
3
Total length of participation:
134 weeks
134 weeks
Looking for Specific Volunteers
Able to participate:
- Generalized myasthenia Gravis
- AChR antibody positive status
Not eligible if:
- Pregnancy
- other autoimmune conditions
Contact the Team
Visit Location
Contact & Visit Location
Primary Contact
- Manisha Chopra
- chopram@neurology.unc.edu
- (919) 843-7857
Primary Visit Location
Clinical and Translational Research Center (CTRC)
Burnett-Womack Building (UNC-Chapel Hill)
160 Dental Cir, Chapel Hill, NC 27514, USA
Additional Study Information
Principal Investigator
James Howard
Neurology-Neuromuscular
Study Type
Clinical or Medical
Interventional
Study Topics
Bones, Joints, Muscles
Chronic Conditions
IRB Number
23-2163
